To test this hypothesis, this study employs an integrated strategy combining metabolomics with serum-urine pharmacochemistry and network pharmacology to systematically identify AR’s active constituents and elucidate their multi-target mechanisms in T2DM management. The gene discussed is AR; the disease is type 2 diabetes mellitus.